Novo Nordisk Lifts Prescription Curbs on Wegovy

COPENHAGEN (Reuters) – Novo Nordisk (NYSE:NVO) is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, according to CEO Lars Fruergaard Jorgensen.

“In our guidance for the full year, you can assume that there is a step up in the fourth quarter and that's partly driven by increased products including Wegovy into the U.S.,” Jorgensen told Reuters in an interview.

He noted that the slower pace of weekly prescriptions for Wegovy in the U.S. over the last few months resulted from lower starter doses being supplied into the market.

“You can find different periods of times where you can say it's plateauing but it's not because of plateaued demand, it's simply because of the supply into the market,” Fruergaard said.